Another monoclonal antibody, functioning as a channel blocker and able to inhibit Kv10.1 current, was shown to not only reduce the growth of cancer cells in vitro, but also tumour progression in vivo in subcutaneous MDA-MB-435S xenografts and in human pancreatic cancer explants (Gomez-Varela et al. 2007). Here, KCNH1 is linked to familial pancreatic carcinoma.